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OBJECTIVES: Idiopathic central precocious puberty and its postponement with a (gonadotropin-releasing hormone)
GnRH agonist are complex conditions, the final effects of which on bone mass are difficult to define. We evaluated
bone mass, body composition, and bone remodeling in two groups of girls with idiopathic central precocious
puberty, namely one group that was assessed at diagnosis and a second group that was assessed three years after
GnRH agonist treatment.
METHODS: The precocious puberty diagnosis and precocious puberty treatment groups consisted of 12 girls
matched for age and weight to corresponding control groups of 12 (CD) and 14 (CT) girls, respectively. Bone mineral
density and body composition were assessed by dual X-ray absorptiometry. Lumbar spine bone mineral density was
estimated after correction for bone age and the mathematical calculation of volumetric bone mineral density.
CONEP: CAAE-0311.0.004.000-06.
RESULTS: Lumbar spine bone mineral density was slightly increased in individuals diagnosed with precocious
puberty compared with controls; however, after correction for bone age, this tendency disappeared (CD= -0.74¡0.9
vs. precocious puberty diagnosis = -1.73¡1.2). The bone mineral density values of girls in the precocious puberty
treatment group did not differ from those observed in the CT group.
CONCLUSION: There is an increase in bone mineral density in girls diagnosed with idiopathic central precocious
puberty. Our data indicate that the increase in bone mineral density in girls with idiopathic central precocious
puberty is insufficient to compensate for the marked advancement in bone age observed at diagnosis. GnRH agonist
treatment seems to have no detrimental effect on bone mineral density.
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INTRODUCTION
Although the mechanistic process of bone mass gain
remains to be clarified, it is recognized that genetic factors
determine 60 to 80% of peak bone mass and that sex steroids
and growth factors play a pivotal role in the ascending and
descending shape of the bone mineral density (BMD) curve
(1,2).
BMD increases significantly during puberty; it is accepted
that approximately 40% of peak bone mass is acquired
between Tanner stages II and V (1,3) and that the rate of
acquisition is particularly high between stage III and stage
IV (4,5). Thereafter, bone acquisition decelerates, and the
increase continues at a slow rate until bone consolidation
has been completed (6). Gonadal steroids can affect bone
mass acquisition either directly or indirectly through effects
on molecules such as growth hormone, insulin-like growth
factor-1, and 1,25(OH)2 D (6-9). Under normal circum-
stances, pubertal gonadotropin production in females leads
to the increased conversion of C19 steroids (androstene-
dione and testosterone) to estrogens, which in turn results in
growth acceleration, skeletal maturation and epiphyseal
fusion (10). BMD at the radius and lumbar spine levels has
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been found to be significantly higher in girls with
precocious puberty compared with prepubertal girls
(11,12). Moreover, delayed puberty is associated with
reduced bone mass (13-15).
The limited accrual of peak bone mass is so important for
the determination of future bone strength that osteoporosis
has been considered a pediatric disorder with repercussions
(e.g. occurence of fracture) in the elderly population (16,17).
Idiopathic central precocious puberty (iCPP) is a frequent
disorder of gonadal axis development in girls. iCPP and its
treatment with a long-acting agonist of gonadotrophin-
releasing hormone (GnRHa) constitute a complex condition
that includes factors related to both early exposure to
gonadal steroids and a potential delay in the occurrence of
puberty. The consequences of iCPP treatment with regard to
bone mass accrual and body composition in girls remain to
be defined. Previous studies have shown conflicting results;
while some have detected negative effects of GnRHa on
BMD (11,18), others have shown no detrimental effects
(19,20). However, it is necessary to consider that the cited
studies evaluated bone mass over a short period of time or
included a heterogeneous group of patients, i.e., boys, girls
and patients with organic CPP and with early puberty (19),
in addition to individuals with iCPP.
The aim of the present study was to evaluate the early
impact of iCPP on the BMD of treatment-naive girls and the
long-term influence of depot GnRHa on the BMD and body
composition in patients who had completed treatment at
least three years previously.
MATERIALS AND METHODS
Subjects
The study included 50 girls divided into 4 groups: a) 12
girls recently diagnosed with iCPP (PPD), b) 12 pre-pubertal
control girls matched for age and weight to PPD girls (CD),
c) 12 girls previously diagnosed with iCPP who had
completed treatment with GnRHa at least 3 years before
participating in the study (PPT), and d) 14 adolescent girls
who were matched for age and weight to PPT girls (second
control group; CT). The mean ages in the CD, PPD, CT, and
PPT groups were 8.6¡1.2, 8.3¡0.6, 18.6¡2.8, and 17.6¡2.6
years, respectively. The study was approved by the Ethics
Committee of the University Hospital, School of Medicine of
Ribeira˜o Preto, University of Sa˜o Paulo (11462/06). Written
informed consent was obtained from all individuals and/or
their families after they had been informed about the aims,
procedures and risks of the study.
The diagnosis of iCPP was based on the emergence of
secondary pubertal signs before the chronological age (CA) of
8 year, acceleration of the growth rate, bone age advance of
more than 1 year with regard to the CA, and the analysis of
basal and stimulated serum levels of LH. The laboratory test
was considered positive when the basal LH level was .0.6
IU/L and/or .6.9 IU/L after the GnRH stimulation test (21).
All patients with a diagnosis of iCPP underwent a hypotha-
lamic/pituitary MRI evaluation, which yielded normal results.
In all groups, children with a personal and/or family history
of osteometabolic disease and those taking medications that
impact bone mineral metabolism (estrogens, glucocorticoids,
diuretics, and anticonvulsants) were excluded. All children
admitted to the study had normal kidney and hepatic
function. Children with pathological CPP and early pubertal
children were excluded. The selected patients were followed
at the outpatient clinic of Pediatric Endocrinology Division,
University Hospital, School of Medicine of Ribeira˜o Preto,
USP.
Methods
A peripheral blood sample was collected after an over-
night fast and immediately processed to obtain serum;
aliquots were stored at -70 C˚. A second voided urine sample
was collected under standardized conditions from 08:00-
09:00 am. One aliquot was immediately used for creatinine
determination, and a second sample was stored at -70 C˚.
Serum levels of total calcium, inorganic phosphorus and
alkaline phosphatase were determined using an automatic
biochemical analyzer (Dimension RXL, Dade-Behring,
Deerfield, IL, USA). Osteocalcin was measured using an
immunoradiometric (IRMA) method (hOST-IRMA, Biosource
Europe, Nivelles, Belgium). Urinary deoxypyridinoline was
measured using an immunoenzymatic method (ELISA)
(Metra Biosystems, Mountain View, CA, USA). Serum 25-
hydroxyvitamin D (25-OHD) and parathyroid hormone
(PTH) were measured by radioimmunoassay (Diasorin,
Saluggia, VC, Italy) and chemoluminescence (Diagnostic
Products Corporation, Los Angeles, CA, USA), respectively.
The degrees of intra- and interassay variation were 3.6 and
7.5% for osteocalcin, 4.1 and 6.8% for deoxypyridinoline, 5.4
and 8.6% for 25-OHD, and 3.2 and 5.6% for PTH, respectively.
Scans of lumbar spine (L1-L4), total hip and femoral neck
BMD, as well as of total body lean and fat mass, were
obtained by double-energy X-ray absorptiometry (Hologic
4500W, USA). The exams were performed by the same
operator according to rigid positioning criteria standardized
for each target site. The BMD results are reported as areal
BMD (g/cm2) and Z-scores. The Z-scores were re-evaluated
after adjustment for bone age (BABMD). In addition,
volumetric density of the lumbar spine (aBMD) was also
estimated mathematically in L2-L4, as proposed by Carter et
al. (22), using the following equation: aBMD = a/b, where a
is the BMD (in g/cm2) of the lumbar spine (L2-L4) and b is
the square root of the bone area (in cm2) of the lumbar spine
(L2-L4).
The precision errors of BMD measurements were 1.2% for
the lumbar spine (L1-L4), 1.9% for the femoral neck, and
2.9% for the total femur. Low BMD was defined using the
criteria of the International Society of Clinical Densitometry,
i.e., a Z-score of -2.0 or less adjusted for age and gender (23).
Bone age and BABMD were determined as described
previously (24).
The results are reported as the means¡SD. Statistical
analysis was performed by considering two groups each
time (e.g., the iCPP and corresponding age-matched control
groups). The results were analyzed by the nonparametric
Mann-Whitney test, and correlations between parameters
were analyzed using the Spearman test. Statistical analysis
was performed using GraphPad Prism 3.0 software (1999;
GraphPad Prism, San Diego, CA, USA). The level of
significance was set at 5% in all analyses.
RESULTS
Children at diagnosis
Table 1 shows that there was no significant difference in
age, weight, height, or BMI between the CD and PPD
groups. However, bone age (BA) was significantly increased
in patients diagnosed with iCPP (CD = 9.7¡2.2 vs.
BMD in idiopathic precocious puberty
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PPD = 12.0¡0.7 years; p,0.0005). Serum levels of LH and
estradiol, but not FSH, were also significantly increased in
the PPD group.
There were no significant differences in serum calcium,
phosphorus or alkaline phosphatase, PTH or 25(OH)D
levels between CD and PPD patients (Table 2). The
biochemical markers of bone formation (osteocalcin) and
of bone resorption (deoxypyridinoline) were similar in PPD
and CD patients (Table 2).
There was no significant difference in total body BMD
between the CD and PPD groups (Table 3). The BMD of
the lumbar spine in PPD patients was not significantly
higher than that in the corresponding control girls
(CD = 0.613¡0.08 vs. PPD = 0.633¡0.09 g/cm2). However,
when BMD at L1-L4 was expressed as the Z-score corrected
for BA, BABMD tended to decrease in children with PPD
(CD = -0.74¡0.9 vs. PPD = -1.73¡1.2 SD; p,0.06). The
estimated volumetric density was similar between the
groups (CD = 0.113¡0.01 vs. PPD = 0.114¡0.01 g/cm3).
Total hip BMD was significantly higher in PPD patients
(0.693¡0.05) compared with the control group (0.625¡0.05)
(p,0.007).
Table 3 shows the body composition results for both
groups. There was no significant difference between groups
regarding body composition parameters, including %FM
(CD = 17.7¡6.6% vs. PPD = 19.7¡6.6%). Serum levels of
estrogen were significantly correlated with fat mass in the
PPD group (r = 0.98; p,0.0001).
iCPP Girls after GnRHa treatment
Table 1 shows that there were no significant differences
in age, weight or BMI between the group of patients
previously treated with GnRHa and the control group, but
height was significantly higher in CT (1.63¡0.04 m) than in
PPT (1.57¡0.04 m) patients (p,0.01).
The serum levels of pituitary/gonadal axis hormones
(LH, FSH and estradiol) did not differ significantly between
groups. Serum alkaline phosphatase levels were signifi-
cantly lower in the PPT group (184¡146 IU/L) than in the
CT group (323¡214 IU/L) (p,0.01), but there was no
significant difference between groups in the serum levels
of calcium, phosphorus, PTH or 25(OH)D (Table 2). Serum
osteocalcin levels and urinary DPD levels were slightly
lower in PPT compared with CT patients.
Table 1 - The clinical characteristics of control groups (CD and CT) and of patients with idiopathic central precocious
puberty (iCPP) at diagnosis (PPD) and after treatment (PPT) with GnRHa.
Data
CD
(n=12)
PPD
(n=12) p-value
CT
(n= 14)
PPT
(n = 12) p-value
Age
(years)
8.6¡1.2 8.3¡0.6 0.5 18.6¡2.8 17.6¡2.6 0.4
Bone age
(years)
9.7¡2.2 12.0¡0.7* 0.005 17.3¡1.2 17.4¡0.8 0.8
Weight
(kg)
35.4¡9.5 41.2¡11.0 0.2 61.7¡10.8 59.5¡132 0.5
Height
(m)
1.38¡0.1 1.41¡0.08 0.4 1.63¡0.04 1.57¡0.04* 0.01
BMI
(kg/m2)
18.5¡3.8 20.4¡4.0 0.3 23.2¡3.8 24.0¡5.2 0.9
LH
(IU/L)
0.69¡1.3 4.15¡3.0* 0.005 5.23¡5.12 6.3¡4.5 0.58
FSH
(IU/L)
3.1¡1.6 5.9¡3.8 0.1 3.4¡2.1 4.9¡2.9 0.15
Estradiol
(pmol/L)
111.6¡40.4 208.1¡83.0* 0.01 168.9¡86.3 319.7¡211.5 0.08
*significant difference between patients with iCPP and the corresponding control group.
Table 2 - Biochemical evaluation of control groups (CD and CT) and of patients with idiopathic precocious central
puberty (iCPP) at the time of diagnosis (PPD) and after treatment with GnRHa (PPT).
Data
CD
(n =12)
PPD
(n=12) p-value
CT
(n= 14)
PPT
(n = 12) p-value
Calcium
(mmol/L)
2.43¡0.18 2.48¡0.23 0.5 2.4¡0,2 2.4¡0.2 0.9
Phosphorus
(mmol/L)
1.62¡0.26 1.84¡0.23 0.08 1.52¡0.29 1.32¡0.13 0.07
Alkaline
phosphatase
(IU/L)
436¡260 562¡196 0.2 323¡214 184¡146* 0.01
PTH
(ng/L)
36.4¡12.8 34.1¡16.5 0.5 32.8¡10.8 39,1¡16.3 0.3
25-OHD
(nmol/L)
75.6¡10.2 79.1¡15.5 0.4 84.1¡13.2 81.4¡18.5 0.44
Osteocalcin (nmol/L) 4.55¡2.68 5.30¡2.50 0.28 7.3¡5.0 6.2¡4.1 0.52
DPD (nmol/mmol) 17.3¡6.2 20.0¡8.2 0.6 11.9¡7.4 7.9¡5.2 0.1
DPD - deoxypyridinoline; *Represents a significant difference between patients with iCPP and the corresponding control group.
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There was no difference in lumbar spine BMD between
the PPT and CT groups, and the same pattern was observed
in both groups after the estimation of volumetric BMD.
Additionally, femoral neck and total hip BMD values were
also similar in these groups (Table 4).
Adolescents with iCPP previously treated with GnRHa
exhibited body composition parameter values similar to
those of the control group, i.e., %FM was not significantly
affected by the previous use of GnRHa (CT = 34.9¡5.1% vs.
PPT = 35.0¡6.7%) (Table 3).
DISCUSSION
Physiological and pathological fluctuations in circulating
estrogen levels are associated with a positive or negative net
imbalance in bone remodeling (25-27). The onset of puberty
represents a unique opportunity for the extra-uterine
acceleration of bone mass gain, and it is well known that
delayed puberty is associated with impaired bone mass
accrual. Conversely, the final effect of the postponement of
the pubertal surge provoked by GnRHa in bone mass
development in girls diagnosed with iCPP remains to be
clarified. The present study shows that, at diagnosis, iCPP
patients tend toward a higher BMD than their correspon-
dent control individuals. However, advancement in bone
age is proportionally greater than the increase in bone mass
in these patients; accordingly, BABMD in the lumbar spine
was almost significantly lower in recently diagnosed iCPP
patients. Additionally, the present data show that the BMD
in patients who had concluded treatment at least three years
prior to enrollment in the study was analogous to that of the
corresponding controls.
Previous studies have shown that BMD was significantly
increased in patients with iCPP and that GnRHa treatment
for 2 years impaired bone mass acquisition in these patients
(18,28). The authors also observed that bone loss was
preventable by calcium supplementation (18). In contrast, in
a more recent study, it was observed that patients with iCPP
exhibited an increase in BMD one year after treatment with
GnRHa (29). In addition, a previous study observed that
BMD corrected for bone age was decreased in iCPP patients
and that this BMD difference decreased after GnRHa
treatment. Similar to previous reports, we observed that
the tendency for iCCP patients to exhibit high absolute BMD
disappeared when the result was adjusted for BA. However,
our data are not directly comparable to those reported in the
studies described above. Whereas the authors of previous
studies evaluated the immediate effect of GnRHa on BMD,
we determined BMD 3 years after the conclusion of
treatment. Therefore, the present investigation is the first
to show that long-term GnRHa treatment allows iCPP girls
to improve their acquisition of bone mass. The insignificant
difference in L1-L4 BMD between iCPP adolescents and
controls vanished after the estimation of volumetric BMD.
Total hip BMD was significantly higher in iCPP children
than in controls. Recently, it was hypothesized that bone
loss at cortical sites is more closely related to estrogen levels
than bone loss in trabecular bone (30). In support of this
proposal, observations based on quantitative computed
tomography showed that the decrease in trabecular bone
mass precedes a decrease in serum estrogen levels, while
cortical bone loss coincides with the occurrence of hypoes-
trogenemia (30,31). Our results do not allow us to conclude
that precocious puberty favors cortical bone gain to the
detriment of trabecular bone. Compared with the control
group, girls recently diagnosed with iCPP showed a slight
increase in BMD at L1-L4, which predominantly reflected an
increase in trabecular bone, and significantly increased
BMD in the total hip, which is composed of a mixture of
trabecular and cortical bone. In parallel, BMD at the distal
1/3 of the forearm, which consists mainly of cortical bone,
was similar in iCPP girls and controls. GnRHa therapy did
not interfere with bone mass gain in bone composed of
distinct mixtures of trabecular and cortical bone. BMD
values in the lumbar spine, distal 1/3 of the forearm and the
Table 4 - Bone mineral density assessment of control groups (CD and CT) and of patients with idiopathic central
precocious puberty (iCPP) at diagnosis (PPD) and after treatment (PPT) with GnRHa.
Data
CD
(n=12)
PPD
(n=12) p-value
CT
(n= 14)
PPT
(n= 12) p-value
L1-L4
(g/cm2)
0.613¡0.08 0.633¡0.09 0.66 0.959¡0.06 0.900¡0,1 0.2
Z-score (DP)
(L1-L4)
-0.5¡1.3 -0.6¡0.8 0.97 0.5¡0.4 -0.9¡0.6 0.2
BAZ-score (DP) (L1-L4) -0.74¡0.9 -1.73¡1.2 0.06 NA NA NA
vL1-L4
(g/cm3)
0.113¡0.01 0.114¡0.01 0.97 0.144¡0.009 0.146¡0.01 0.6
Total hip
(g/cm2)
0.625¡0.05 0.693¡0.05* 0.01 0.908¡0.1 0.893¡0.1 0.6
Femoral neck
(g/cm2)
0.630¡0.07 0.689¡0.06 0.09 0.888¡0.1 0.861¡0.1 0.6
1/3 Radius/forearm
(g/cm2)
0.485¡0.05 0.465¡0.04 0.37 0.652¡0.02 0.640¡0.06 0.3
NA=not available; * significant difference between patients with iCPP and the corresponding control group.
Table 3 - Body composition and total body bone mineral
density in the control groups (CD and CT) and in patients
with idiopathic central precocious puberty at diagnosis
(PPD) and after treatment (PPT) with GnRHa.
Data
CD
(n=12)
PPD
(n=12)
p-
value
CT
(n= 14)
PPT
(n= 12)
p-
value
BMD
(g/cm2)
1.012¡0.2 1.145¡0.2 0.1 1.433¡0.2 1.386¡0.3 0.4
Lean Mass
(kg)
21.1¡13.9 19.3¡10.0 0.8 37.3¡4.4 35.7¡5.6 0.2
Fat Mass
(kg)
17.7¡6.6 19.7¡6.6 0.5 21.6¡6.6 21.2¡8.7 0.5
Fat % 34.1¡ 9.5 32.3¡9.7 0.7 34.9¡5.1 35.0¡6.7 0.7
BMD in idiopathic precocious puberty
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proximal femur of iCPP adolescents submitted to this
treatment were analogous to control values.
Evidence connecting bone to adipose tissue and both to the
endocrine control of intermediary metabolism has emerged
in recent years. Osteocalcin from osteoblasts and leptin and
adiponectin from adipocytes are some of the molecules
involved in these new networks (32-34). Curiously, pubertal
onset seems to be closely related to adipose tissue volume,
meaning that leptin may be a link between potential
alterations in skeletal and intermediary metabolism asso-
ciated with pubertal onset (35). Therefore, there is great
interest in the study of body composition in iCPP, particu-
larly in the fat compartment due to its potential effects on
insulin sensitivity. Our results show that neither children
with the diagnosis of iCPP nor adolescents who have
received long-term treatment with GnRHa display altera-
tions in body mass composition. Moreover, %FM in the
group of adolescents previously treated with GnRHa was
equivalent to that of the control group. In a recent clinical
investigation, it was suggested that carboxylated osteocalcin
and undercarboxylated osteocalcin are both associated with
insulin sensitivity. Our results show that serum osteocalcin
levels in patients with iCPP before and after treatment are
similar to those of their corresponding control groups.
This study has some limitations. The number of patients
studied was insufficient to definitively exclude the impact
of GnRHa on bone in individuals with iCPP. Additionally,
our study has a cross-sectional design and did not allow for
the estimation of an increase in bone mass during GnRHa
therapy. However, these are important preliminary data for
a more comprehensive study examining the impact of iCPP
and its treatment on bone mass development.
In summary, our results show that BMD is not particu-
larly affected by iCPP in girls and that the treatment of iCPP
with GnRHa does not seem to have a detrimental effect on
the acquisition of bone mass. We also observed that iCPP
has no remarkable effect on body composition. The
limitation of growth rate continues to be the major issue to
be improved in the treatment of girls who have precociously
entered puberty.
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